Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells

Molecular and Cellular Endocrinology

Volumn 350, Issue 1, 2012, Pages 107-117

  Varisli, Lokman ^a   Gonen Korkmaz, Ceren ^b   Syed, Hamid Muhammad ^a   Bogurcu, Nuray ^a,c   Debelec Butuner, Bilge ^a   Erbaykent Tepedelen, Burcu ^a   Korkmaz, Kemal Sami ^a  

^a EGE UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Akt signaling; Androgen receptor; HN1; Transcriptional regulation; Ubiquitination

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANDROGEN; ANDROGEN RECEPTOR; PROTEASOME; PROTEIN KINASE B; SMALL INTERFERING RNA;

ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DOWN REGULATION; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INTERACTION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC CORRELATION; HEMATOLOGICAL AND NEUROLOGICAL EXPRESSED 1 GENE; INTRACELLULAR SIGNALING; KLK3 GENE; KLK4 GENE; MEDIATOR RELEASE; NKX3.1 GENE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; STAMP2 GENE; STEADY STATE; TRANSACTIVATION; UBIQUITINATION; UPREGULATION;

ANDROGENS; CELL LINE, TUMOR; CELL PROLIFERATION; DEXAMETHASONE; ESTRADIOL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; KALLIKREINS; LEUPEPTINS; MALE; METRIBOLONE; NERVE TISSUE PROTEINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN TRANSPORT; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; TRANSCRIPTIONAL ACTIVATION;

EID: 84856057491     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.11.027     Document Type: Article

References (42)

1. Brinkmann A.O., Blok L.J., de Ruiter P.E., Doesburg P., Steketee K., Berrevoets C.A., Trapman J. Mechanisms of androgen receptor activation and function. J. Steroid Biochem. Mol. Biol. 1999, 69:307-313.
2. Bruchovsky, N., Klotz, L.H., Sadar, M., Crook, J.M., Hoffart, D., Godwin, L., Warkentin, M., Gleave, M.E., Goldenberg, S.L., 2000, Intermittent androgen suppression for prostate cancer: canadian prospective trial and related observations. Mol. Urol. 4, 191-199 (discussion 201).
3. Cartharius K., Frech K., Grote K., Klocke B., Haltmeier M., Klingenhoff A., Frisch M., Bayerlein M., Werner T. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005, 21:2933-2942.
4. Centenera M.M., Harris J.M., Tilley W.D., Butler L.M. The contribution of different androgen receptor domains to receptor dimerization and signaling. Mol. Endocrinol. 2008, 22:2373-2382.
5. Chang C.J., Mulholland D.J., Valamehr B., Mosessian S., Sellers W.R., Wu H. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol. Cell. Biol. 2008, 28:3281-3289.
6. Cleutjens C.B., Steketee K., van Eekelen C.C., van der Korput J.A., Brinkmann A.O., Trapman J. Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology 1997, 138:5293-5300.
7. Culig Z., Steiner H., Bartsch G., Hobisch A. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr. Relat. Cancer 2005, 12:229-244.
8. Denmeade S.R., Lin X.S., Isaacs J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996, 28:251-265.
9. Galigniana M.D., Housley P.R., DeFranco D.B., Pratt W.B. Inhibition of glucocorticoid receptor nucleocytoplasmic shuttling by okadaic acid requires intact cytoskeleton. J. Biol. Chem. 1999, 274:16222-16227.
10. Goto T., Hisatomi O., Kotoura M., Tokunaga F. Induced expression of hematopoietic- and neurologic-expressed sequence 1 in retinal pigment epithelial cells during newt retina regeneration. Exp. Eye Res. 2006, 83:972-980.
11. Graff J.R., Konicek B.W., McNulty A.M., Wang Z., Houck K., Allen S., Paul J.D., Hbaiu A., Goode R.G., Sandusky G.E., Vessella R.L., Neubauer B.L. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J. Biol. Chem. 2000, 275:24500-24505.
12. Gregory C.W., Johnson R.T., Mohler J.L., French F.S., Wilson E.M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001, 61:2892-2898.
13. Hakariya T., Shida Y., Sakai H., Kanetake H., Igawa T. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells. Biochem. Biophys. Res. Commun. 2006, 342:92-100.
14. Hsing A.W. Hormones and prostate cancer: what's next?. Epidemiol. Rev. 2001, 23:42-58.
15. Hsing A.W., Reichardt J.K., Stanczyk F.Z. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002, 52:213-235.
16. Huang G.M., Ng W.L., Farkas J., He L., Liang H.A., Gordon D., Yu J., Hood L. Prostate cancer expression profiling by cDNA sequencing analysis. Genomics 1999, 59:178-186.
17. Huggins C. Endocrine-induced regression of cancers. Science 1967, 156:1050-1054.
18. Korkmaz C.G., Korkmaz K.S., Kurys P., Elbi C., Wang L., Klokk T.I., Hammarstrom C., Troen G., Svindland A., Hager G.L., Saatcioglu F. Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene 2005, 24:4934-4945.
19. Kumar B., Koul S., Khandrika L., Meacham R.B., Koul H.K. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 2008, 68:1777-1785.
20. Laughlin K.M., Luo D., Liu C., Shaw G., Warrington K.H., Law B.K., Harrison J.K. Hematopoietic- and neurologic-expressed sequence 1 (Hn1) depletion in B16.F10 melanoma cells promotes a differentiated phenotype that includes increased melanogenesis and cell cycle arrest. Differentiation 2009, 78:35-44.
21. Laughlin K.M., Luo D., Liu C., Shaw G., Warrington K.H., Qiu J., Yachnis A.T., Harrison J.K. Hematopoietic- and neurologic-expressed sequence 1 expression in the murine GL261 and high-grade human gliomas. Pathol. Oncol. Res. 2009, 15:437-444.
22. Li J., Al-Azzawi F. Mechanism of androgen receptor action. Maturitas 2009, 63:142-148.
23. Litvinov I.V., De Marzo A.M., Isaacs J.T. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?. J. Clin. Endocrinol. Metab. 2003, 88:2972-2982.
24. Litvinov I.V., Vander Griend D.J., Antony L., Dalrymple S., De Marzo A.M., Drake C.G., Isaacs J.T. Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc. Natl. Acad. Sci. U S A 2006, 103:15085-15090.
25. Nelson P.S., Clegg N., Arnold H., Ferguson C., Bonham M., White J., Hood L., Lin B. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc. Natl. Acad. Sci. U S A 2002, 99:11890-11895.
26. Novac N., Heinzel T. Nuclear receptors: overview and classification. Curr. Drug Targets Inflamm. Allergy 2004, 3:335-346.
27. Roche P.J., Hoare S.A., Parker M.G. A consensus DNA-binding site for the androgen receptor. Mol. Endocrinol. 1992, 6:2229-2235.
28. Romanuik T.L., Wang G., Morozova O., Delaney A., Marra M.A., Sadar M.D. LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Med. Genomics 2010, 3:43.
29. Shah R.B., Mehra R., Chinnaiyan A.M., Shen R., Ghosh D., Zhou M., Macvicar G.R., Varambally S., Harwood J., Bismar T.A., Kim R., Rubin M.A., Pienta K.J. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004, 64:9209-9216.
30. Sheflin L., Keegan B., Zhang W., Spaulding S.W. Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem. Biophys. Res. Commun. 2000, 276:144-150.
31. Taneja S.S., Ha S., Swenson N.K., Huang H.Y., Lee P., Melamed J., Shapiro E., Garabedian M.J., Logan S.K. Cell-specific regulation of androgen receptor phosphorylation in vivo. J. Biol. Chem. 2005, 280:40916-40924.
32. Tang W., Lai Y.H., Han X.D., Wong P.M., Peters L.L., Chui D.H. Murine Hn1 on chromosome 11 is expressed in hemopoietic and brain tissues. Mamm. Genome 1997, 8:695-696.
33. Taniguchi A., Hasegawa Y., Higai K., Matsumoto K. Transcriptional regulation of human beta-galactoside alpha2, 6-sialyltransferase (hST6Gal I) gene during differentiation of the HL-60 cell line. Glycobiology 2000, 10:623-628.
34. Tomlins S.A., Mehra R., Rhodes D.R., Cao X., Wang L., Dhanasekaran S.M., Kalyana-Sundaram S., Wei J.T., Rubin M.A., Pienta K.J., Shah R.B., Chinnaiyan A.M. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 2007, 39:41-51.
35. van der Kwast T.H., Schalken J., Ruizeveld de Winter J.A., van Vroonhoven C.C., Mulder E., Boersma W., Trapman J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer 1991, 48:189-193.
36. Varisli, L., Gonen-Korkmaz, C., Debelec-Butuner, B., Erbaykent-Tepedelen, B., Muhammed, H.S., Bogurcu, N., Saatcioglu, F., Korkmaz, K.S., 2011, Ubiquitously expressed hematological and neurological expressed 1 downregulates Akt-mediated GSK3beta signaling, and its knockdown results in deregulated G2/M transition in prostate cells. DNA Cell Biol.
37. Veldscholte J., Berrevoets C.A., Mulder E. Studies on the human prostatic cancer cell line LNCaP. J. Steroid Biochem. Mol. Biol. 1994, 49:341-346.
38. Wen Y., Hu M.C., Makino K., Spohn B., Bartholomeusz G., Yan D.H., Hung M.C. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000, 60:6841-6845.
39. Wouters A., Pauwels B., Lambrechts H.A., Pattyn G.G., Ides J., Baay M., Meijnders P., Lardon F., Vermorken J.B. Counting clonogenic assays from normoxic and anoxic irradiation experiments manually or by using densitometric software. Phys. Med. Biol. 2010, 55:N167-178.
40. Zhou G., Wang J., Zhang Y., Zhong C., Ni J., Wang L., Guo J., Zhang K., Yu L., Zhao S. Cloning, expression and subcellular localization of HN1 and HN1L genes, as well as characterization of their orthologs, defining an evolutionarily conserved gene family. Gene 2004, 331:115-123.
41. Zhu M.L., Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr. Relat. Cancer 2008, 15:841-849.
42. Zujovic V., Luo D., Baker H.V., Lopez M.C., Miller K.R., Streit W.J., Harrison J.K. The facial motor nucleus transcriptional program in response to peripheral nerve injury identifies Hn1 as a regeneration-associated gene. J. Neurosci. Res. 2005, 82:581-591.